Highest-materiality recent filing
Director Mickie Henshall not standing for re-election; board reduces to 7 directors
Mickie Henshall notified board she will not stand for re-election at the 2026 Annual Meeting.
VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test
Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.
VolitionRx completes 1-for-20 reverse stock split effective April 28, 2026
Stockholders approved reverse split at special meeting March 31, 2026; Board set ratio at 1:20.
NYSE American accepts VolitionRx compliance plan; shares continue trading until Aug 2027 review
Received non-compliance notice on Feb 6, 2026 for stockholders' equity deficiency (below $2M threshold).
VolitionRx board approves 1-for-20 reverse stock split effective April 28, 2026
Reverse stock split ratio set at 1-for-20, effective 12:01 a.m. ET on April 28, 2026.
VolitionRx shareholders approve share issuance to Lind Global and reverse stock split authorization
Proposal 1 (issuance >20% to Lind Global): 44.15M for, 14.10M against, 1.11M abstain, 21.15M broker non-votes approved.
VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%
Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.
VolitionRx issues 6.4M shares to Lind Global to satisfy $1.42M debt payments
Feb 17, 2026: issued 1,956,178 shares to Lind Global for $416,666 payment.
Received NYSE American notice on Feb 6, 2026 for failing $2M, $4M, $6M stockholders' equity thresholds due to sustained losses.
VolitionRx secures $2.0M funding from Lind Global with convertible note and warrants
Gross proceeds $2M; issues $2.4M senior secured convertible note and 7,000,350 warrants at $0.5714/share.
VolitionRx subsidiary CEO Dr. Butera to depart Jan 31, 2026; position eliminated
Volition Veterinary CEO Dr. Salvatore Thomas Butera given termination notice, effective Jan 31, 2026.
VolitionRx amends over-allotment terms; underwriter buys 1.19M shares and 1.73M warrants
Amendment permits separate exercise of over-allotment shares and warrants, not just combined.
VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic
Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.
Amendment allows Over-Allotment Option to be exercised separately for shares and/or warrants, not combined.
VolitionRx over-allotment exercised: 1.19M shares & 1.73M warrants sold at $0.52/unit
Underwriter exercised over-allotment option for 1,194,000 shares and 1,732,500 warrants at $0.52 per unit.
VolitionRx raises $6M in underwritten offering; only $0.3M cash pre-offering
Gross proceeds $6.0M from 11.55M units at $0.52; net ~$5.4M after underwriting discounts and expenses.
VolitionRx Q2 2025 revenue ~$0.4M; net loss down 11% YoY; expects first human licensing deal
Q2 2025 revenue just over $0.4M; H1 2025 revenue up 15% YoY.
VolitionRx raises $1.21M in registered direct offering; insiders buy stock
156,250 shares sold to directors/officers at $0.64/share; 1,734,375 shares + warrants at $0.64/unit.
VolitionRx shareholders approve authorized share increase to 325M; all director nominees elected
Authorized common shares increased from 175M to 325M effective June 18, 2025, via Certificate of Second Amendment.
On May 12, 2026, Mickie Henshall notified the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of her decision not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).
Max materiality 0.80 · Median 0.60 · Most common event other_material